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Hypothalamic neurons containing orexin (hypocretin)
are activated during motivated behaviors and active
waking. We show that injection of orexin-A into the
ventromedial hypothalamus (VMH) of mice or rats
increased glucose uptake and promoted insulin-
induced glucose uptake and glycogen synthesis in
skeletal muscle, but not in white adipose tissue, by
activating the sympathetic nervous system. These
effects of orexin were blunted in mice lacking b-
adrenergic receptors but were restored by forced
expression of the b2-adrenergic receptor in both my-
ocytes and nonmyocyte cells of skeletal muscle.
Orexin neurons are activated by conditioned sweet
tasting and directly excite VMH neurons, thereby
increasingmuscle glucosemetabolism and its insulin
sensitivity. Orexin and its receptor in VMH thus play
a key role in the regulation of muscle glucose metab-
olism associated with highly motivated behavior by
activating muscle sympathetic nerves and b2-adren-
ergic signaling.
INTRODUCTION
Energy homeostasis, as determined by the balance between
calorie intake and energy expenditure, is regulated by intercon-
nected neuroendocrine and autonomic pathways emanating
from and controlled by the central nervous system (Flier, 2004).
The hypothalamus, a key component of the system for regulation
of energy homeostasis, continuously monitors signals that466 Cell Metabolism 10, 466–480, December 2, 2009 ª2009 Elsevierreflect energy status and initiates appropriate behavioral and
metabolic responses (Schwartz et al., 2000). It thus controls
glucose utilization in insulin-sensitive organs, such as skeletal
muscle, as well as whole-body energy metabolism (Sudo et al.,
1991; Kamohara et al., 1997; Haque et al., 1999; Minokoshi
et al., 1999).
Skeletal muscle is a principal site for glucose and fatty acid
metabolism and is responsible for insulin resistance associated
with obesity and type 2 diabetes mellitus (Kahn and Flier,
2000). Recent studies indicate that the hypothalamus regulates
muscle glucose metabolism and its insulin sensitivity. We have
previously shown that electrical stimulation of the ventromedial
hypothalamus (VMH) increases glucose uptake in certain periph-
eral tissues, including skeletal muscle, brown adipose tissue
(BAT), and heart of rats (Sudo et al., 1991). Intravenous (i.v.) or
intracerebroventricular (i.c.v.) administration of leptin also
induces an acute increase in both whole-body glucose turnover
and glucose uptake by the same peripheral tissues in mice
without any substantial change in plasma insulin or glucose level
(Kamohara et al., 1997). We showed that injection of leptin into
the medial hypothalamus (MH) increases glucose uptake in skel-
etal muscle, heart, and BAT via sympathetic nerves (Haque et al.,
1999; Minokoshi et al., 1999) and in a manner that apparently is
dependent on b-adrenergic receptor (b-AR) stimulation (Haque
et al., 1999). Moreover, injection of leptin into the MH resulted
in the stimulation of fatty acid oxidation in skeletal muscle
through the activation of sympathetic nerves and of a2
subunit-containing AMP kinase (a2AMPK) in skeletal muscle
(Minokoshi et al., 2002).
Orexin-A and -B (also known as hypocretin-1 and 2) are
a pair of neuropeptides expressed by a specific population of
neurons in the lateral (LH) and perifornical areas of the hypothal-
amus (Sakurai et al., 1998; de Lecea et al., 1998). They areInc.
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the prepro-orexin gene (Sakurai et al., 1998; de Lecea et al.,
1998). The orexin-containing neurons are activated during moti-
vated behaviors and active waking (Sakurai, 2007), and they
regulate sympathetic tone, metabolic rate, and blood glucose
concentration as well as food intake, wakefulness, and reward
seeking (Harris et al., 2005; de Lecea et al., 2006; Sakurai,
2007; Tsuneki et al., 2008). The actions of the orexin peptides
are mediated by orexin receptor type 1 (OX-R1) and OX-R2,
which are widely expressed in the brain, including hypothalamic
nuclei such as VMH, paraventricular nucleus (PVH), and ARH
(Marcus et al., 2001). Human narcolepsy, which is accompanied
by a specific loss of hypothalamic orexin neurons, is associated
with metabolic abnormalities, including an increased incidence
of type 2 diabetes and obesity (Schuld et al., 2000). Deficiency
in orexin neurons as a result of expression of ataxin-3 leads to
manifestation of obesity with hypophagia (Hara et al., 2001).
Furthermore, orexin transgenic mice were recently found to
exhibit enhanced insulin sensitivity with regard to whole-body
glucose metabolism (Funato et al., 2009).
Because orexin increases sympathetic outflow (Shirasaka
et al., 1999) and because OX-Rs are abundant in theMH (Marcus
et al., 2001), we hypothesized that hypothalamic orexin and its
receptors in the MHmight stimulate muscle glucose metabolism
via the sympathetic nervous system, similar to the effect of lep-
tin. Here, we show that orexin neurons and its receptor in VMH
play an important role in the regulation of muscle glucosemetab-
olism by preferentially activating muscle sympathetic nerves.
The orexin system is activated by a nonhomeostatic regulatory
system associated with taste stimulation and regulates muscle
glucose metabolism in response to feeding.
RESULTS
Orexin-A Injection into the MH Increases Muscle
Glucose Uptake
We first examined the effect of orexin-A injection into the MH on
whole-body glucose turnover in Sprague-Dawley rats. Orexin-A
injection (5 pmol) into the MH resulted in an increase in basal
whole-body glucose turnover without any glucose and insulin
injection (Figure 1A, left panel). Plasma glucose level did not
change after injection of orexin-A (Figure 1A, right panel), sug-
gesting an increase in both glucose utilization and production.
Injection of orexin-A did also not increase plasma insulin or
epinephrine concentrations (or the plasma glucose concentra-
tion) for up to 4 hr after the injection (see Table S1 available
online).
We next examined 2-deoxy-D-glucose (2DG) uptake in
peripheral tissues. The rate constant of 2DG uptake in skeletal
muscle was significantly increased at 2 hr after injection of
orexin-A (5 pmol) into the MH (Figure 1B). This effect was
more pronounced in the red type of muscle (2.7-fold increase
in the soleus) than in the white type (1.7-fold increase in white
gastrocnemius). In contrast, 2DG uptake in white adipose
tissue (WAT) was not affected (Figure 1B). Uptake of 2DG in
muscle was maximal at 2 hr after orexin-A injection and had
returned to baseline levels by 4 hr (Figure 1C). Injection of
lower dose of orexin-A (0.5 pmol) increased 2DG uptake in
the soleus, but the effect was smaller than that of 5 pmolCell Morexin-A (Figure S1A). Orexin-B (5 pmol) injection into VMH
also increased 2DG uptake in the soleus but not in the other
muscles examined or in WAT at 2 hr after injection (Fig-
ure S1B).
We injected orexin peptides into the VMH portion of the MH
because we previously showed that the VMH is the most effec-
tive site for increasing glucose uptake in skeletal muscle in
response to electrical stimulation or injection of leptin (Sudo
et al., 1991; Minokoshi et al., 1999). Orexin-A remained largely
restricted to VMH at 2 hr after the injection; a small amount of
orexin-A was detected in the ARH, but this amount did not differ
significantly from that in the control (uninjected) side of the ARH
in the same animals (Figure 1D). Injection of orexin-A into the
PVH or LH did not affect 2DG uptake in skeletal muscle or
WAT (data not shown). These results thus suggest that VMH is
the target site for orexin-A in its induction of 2DG uptake in
muscle.
The i.c.v. injection of orexin-A or orexin-A injection into the
ARH has been shown to stimulate feeding behavior and locomo-
tion (Kotz, 2006). However, orexin-A injected into the VMH had
no effect on food intake or locomotor activity (Figures 1E and
1F), as described elsewhere (Dube et al., 1999).
We next determined norepinephrine (NE) turnover in periph-
eral tissues by assessing the decrease in tissue NE content
after inhibition of catecholamine (CA) synthesis. NE turnover
was increased in skeletal muscle, but not in WAT, in response
to orexin-A administration (Figure 1G). Furthermore, prior
administration of guanethidine, a blocker of sympathetic nerve
activity but not of CA secretion from the adrenal medulla (Lund-
berg et al., 1986), completely inhibited the stimulatory effect of
orexin-A on 2DG uptake in the soleus and extensor digitorum
longus (EDL) (Figure 1H). These results suggest that sympa-
thetic nerve in skeletal muscle is activated preferentially by
injection of orexin-A into the MH and regulates muscle 2DG
uptake.
Orexin-A-Induced Muscle Glucose Uptake Requires
b2-AR Signaling in Muscle Cells
In rats, leptin injection into the MH increases 2DG uptake in
muscle via a b-adrenergic mechanism (Haque et al., 1999). We
therefore examined the effect of orexin-A injected into the
VMH on glucose uptake in b1-, b2-, and b3-AR triple-knockout
mice (b-less mice). Orexin-A did not increase muscle 2DG
uptake in b-less mice, whereas it did so in red and mixed types
of muscle, but not in white muscle or WAT, of wild-type (WT)
mice (Figure 2A). Consistent with the results obtained from
rats, orexin-A injection did not alter plasma glucose or insulin
concentrations for 2 hr after the injection (Figure S2A). Orexin-
A did also not affect food intake or plasma glucose and insulin
levels in WT mice (Figures S2B and S2C). Neither locomotor
activity nor the electromyogram of back muscle differed
between WT mice injected with saline and those injected with
orexin-A (Figures S2D and S2E). The activity of muscle
a2AMPK, which is regulated by a-AR signaling (Minokoshi
et al., 2002), was not affected by orexin-A in WT mice (Fig-
ure S2F). These results indicate that orexin-A–induced muscle
glucose uptake is not attributable to muscle contraction, insulin
secretion, or a change in AMPK activity.etabolism 10, 466–480, December 2, 2009 ª2009 Elsevier Inc. 467
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Figure 1. Injection of Orexin-A into VMH of Rats Increases 2DG Uptake in Skeletal Muscle through Activation of the Sympathetic Nervous
System
(A) Glucose turnover rate (left, n = 5) and time course of plasma glucose concentration (right, n = 5) after orexin-A (5 pmol) or saline injection into VMH. *p < 0.05,
**p < 0.01 versus saline-injected animals or other control.468 Cell Metabolism 10, 466–480, December 2, 2009 ª2009 Elsevier Inc.
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affects the insulin signaling pathway in skeletal muscle.
Orexin-A increased the levels of phosphorylation of insulin
receptor substrate–1 (IRS-1) at the YXXM (p85 binding) motif,
of Akt on Ser437, and of AS160 on Thr642, but it did not affect
that of the b subunit of the insulin receptor (IR) on Tyr1146, in
the soleus of WT mice. It had no effect on the phosphorylation
of any of these proteins in b-less mice (Figure 2B). Furthermore,
orexin-A increased the amount of phosphoinositide (PI)
3–kinase activity associated with IRS-1 in WT mice but not in
b-less mice (Figure 2C). These results thus suggest that
orexin-A increases glucose uptake in muscle by activating the
insulin signaling pathway (but not IR) via muscle sympathetic
nerves and b-ARs.
The soleus of mice preferentially expresses the b2 isoform of
b-ARs (Figure 2D). Intraperitoneal (i.p.) injection of the b2-adren-
ergic antagonist ICI 118551, but not that of the b1-adrenergic
antagonist CGP 20712, inhibited orexin-A-induced glucose
uptake in the soleus (Figure 2E). Those antagonists appear to
be specific to b1- and b2-adrenergic receptors, respectively,
because CGP 20712, but not ICI 118551, significantly reduced
the heart rate (Figure S3A). ICI 118551 did also not affect the
orexin-A-induced increase in NE turnover in the soleus (Fig-
ure S3B). These results suggest that ICI 118551 suppressed
orexin-A-induced glucose uptake by inhibiting the b2-adren-
ergic receptor in the soleus but not the sympathetic nerve
activity.
To examine further the role of the b2-AR in skeletal muscle, we
restored expression of the b2-AR in the soleus and red portion of
the gastrocnemius in the right hind limb of b-lessmice by electro-
poration with an expression construct controlled by the skeletal
muscle–specific promoter of the human skeletal muscle actin
(HSA) gene (Brennan and Hardeman, 1993) (Figures 2F–2H).
RT-PCR analysis revealed the presence of b2-AR mRNA in the
right soleus (74.2% ± 13.3% of the amount in WT mice; n = 5)
and red gastrocnemius (67.8% ± 20.4% of the amount in WT
mice; n = 5), but not in the white gastrocnemius or EDL, of the
modified mice (Figure 2F). Although injection of orexin-A into
VMH increased 2DG uptake to similar extents in skeletal muscle
on both sides of WT mice (data not shown), it significantly
increased this parameter in the right soleus and red gastrocne-
mius of the modified animals, compared with that observed in
the control muscle on the left that had been transfected with
the empty vector alone (Figure 2G). Uptake of 2DG in these
muscles of the engineered mice was not affected by injection
of saline into VMH (Figure 2H). These results suggest that
b2-ARs expressed in skeletal muscle cells contribute to orexin-
A-induced 2DG uptake in this tissue.Cell MVMH Is a Target of Orexin-A for Muscle Glucose Uptake
Measurement of orexin-A-like immunoreactivity in hypotha-
lamic nuclei revealed that orexin-A was largely restricted to
VMH of mice at 2 hr after its injection into this nucleus, with
a small amount of the peptide also being detected in the dor-
somedial hypothalamus (DMH) (Figure 3A). Together, our data
from rats and mice thus implicate VMH as an important target
within the MH for orexin-A in its induction of 2DG uptake in
muscle. Immunohistofluorescence analysis revealed that the
mouse VMH contains many orexin-positive processes
(Figure 3B), some of which are located in close proximity to
neurons positive for SF1/Ad4BP, a specific marker for VMH
(Parker et al., 2002; Shima et al., 2005). Furthermore, electro-
physiological recording of the membrane potential of mouse
VMH neurons within brain slices (Figure 3C) revealed that
bath application of orexin-A (500 nM) increased the firing
rate of 73% (16/22) of these neurons and that this effect
was reversible after washout of the peptide (Figure 3D). All
neurons examined (3/3) depolarized (7.5 ± 0.8 mV) in response
to orexin-A even in the presence of 1 mM tetrodotoxin, sug-
gesting that orexin-A directly activates some VMH neurons
(Figure 3E).
The stimulatory effects of orexin-A on NE turnover (Figure 3F)
and 2DG uptake (Figure 3G) in the soleus and EDL were signifi-
cantly inhibited by prior bilateral injection of the OX-R antagonist
SB334867 (Smart et al., 2001) into VMH. Orexin-A activates
neuropeptide Y (NPY)–containing neurons in the ARH (Horvath
et al., 1999). However, i.c.v. injection of NPY or agouti-related
peptide (AgRP) did not induce a significant increase in muscle
glucose uptake (Figure S4), whereas the dose of the injections
significantly increased food intake as reported previously by us
(Fujimoto et al., 2007). These observations thus suggest that
neurons in VMH and nearby areas, but not NPY- and AgRP-
containing neurons, mediate the effect of orexin-A on glucose
uptake in skeletal muscle.
Orexin-A Enhances Insulin-Induced Muscle Glucose
Uptake and Glycogen Synthesis
The effect of orexin-A on glucose uptake was maximal at 2 hr
and had declined by 4 hr after injection (Figure 1C). This time
course differs from that of the effect of leptin on tissue 2DG
uptake, which was observed at 6 hr (Kamohara et al., 1997;
Haque et al., 1999; Minokoshi et al., 1999). We hypothesized
that orexin-A in VMH might contribute to the short-term regula-
tion of muscle glucose metabolism, such as that triggered by
the transient increase in insulin secretion during feeding. We
therefore injected mice with insulin (0.75 U/kg of body mass,
i.v.) 90 min after injection of orexin-A into VMH and measured(B) Rate constant of 2DG uptake in peripheral tissues 2 hr after injection of orexin-A or saline (n = 5–6). Gastro-R, red gastrocnemius; Gastro-W, white gastroc-
nemius; EDL, extensor digitorum longus; WAT (epi), epididymal WAT; WAT (retro), retroperitoneal WAT.
(C) Time course of 2DG uptake in skeletal muscle in response to orexin-A administration (n = 5).
(D) Concentration of orexin-A in hypothalamic nuclei at 2 hr after injection of the peptide into VMH (n = 5). DMH, dorsomedial hypothalamus.
(E) Food intake during the 2-h period after injection of orexin-A or saline (n = 5).
(F) Locomotor activity during the indicated time periods after injection of orexin-A or saline (n = 4).
(G) NE turnover in peripheral tissues after injection of orexin-A. The NE content of tissues (n = 9–10) was measured before (filled circles) and 4 hr after injection of
a-methyl-p-tyrosine (a-MT, intraperitoneal) and either saline (open squares) or orexin-A (filled squares).
(H) Measurement of 2DG uptake in skeletal muscle 2 hr after injection of orexin-A or saline into VMH and 16 hr after i.p. injection of guanethidine (100 mg/kg) or
saline (n = 5). yp < 0.05 versus orexin-A alone. Data are means ± SEM for the indicated numbers (n) of rats. Error bars are shown as SEM.etabolism 10, 466–480, December 2, 2009 ª2009 Elsevier Inc. 469
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Orexin Regulation of Muscle Glucose Metabolism2DG uptake and glycogen synthesis in the soleus 30 min later
(Figure 4A); the blood glucose level was maintained constant
by glucose injection (Figure S5).
Insulin increased the rates of 2DG uptake (Figure 4B) and
glycogen synthesis from glucose (Figure 4C) in the soleus by
factors of 6 and 8, respectively. Although orexin-A injection
alone increased 2DG uptake about two-fold and showed a
tendency to increase glycogen synthesis, it markedly potenti-
ated the insulin effects on both of these processes. Orexin-A
also enhanced the insulin-induced tyrosine phosphorylation of
the IR in the soleus (Figures 4D and 4E), whereas orexin-A injec-
tion alone had no effect on IR phosphorylation (Figures 4D and
4E; also see Figure 2B). The extents of phosphorylation of Akt
on Ser473 and of glycogen synthase kinase 3b (GSK3b) on Ser9
in the soleus induced by insulin plus orexin-A were greater
than those induced by either agent alone (Figures 4D and 4E).
The activity of glycogen synthase a in the soleus was increased
significantly by insulin plus orexin-A (Figure 4F), whereas that of
glycogen phosphorylase a was not affected at 45 min (data not
shown) and was only slightly decreased at 2 hr after orexin-A
injection alone (Figure S6).
Glycogen Synthesis by Orexin-A Plus Insulin Requires
the b2-AR in Nonmyocyte Cells
We next examined the effects of orexin-A and insulin on
glycogen synthesis from glucose in the soleus of b-less mice in
which the b2-AR expression was restored in the right soleus
under the control of the HSA gene promoter. Unexpectedly,
the rate of glycogen synthesis in the right soleus of these animals
treated with the combination of orexin-A and insulin was signifi-
cantly smaller than that in the left soleus (Figure 5A). It was
possible that sympathetic nerves innervating nonmyocyte cells
of skeletal muscle, such as blood vessel cells, are necessary
for induction of glycogen synthesis by orexin-A plus insulin.
We therefore examined the effects of expression of the b2-AR
under the control of the CAG promoter, which confers a high
level of gene expression in all tissues (Niwa et al., 1991). Expres-
sion of the b2-AR under the control of the CAG promoter in the
soleus muscle of b-less mice resulted in a receptor mRNA
abundance that was 80.2% ± 11.2% (n = 6) of that observed in
WT mice (Figure 5B). Electroporation with a vector encoding
enhanced green fluorescent protein (EGFP) under the control
of the CAG promoter conferred EGFP expression not only inCell Mmyocytes but also in nonmyocyte cells, including cells of blood
vessels, whereas the HSA gene promoter yielded EGFP expres-
sion only in myocytes (Figure 5C).
The right soleusmuscle of b-lessmice expressing b2-AR under
the control of the CAG promoter manifested a significantly
greater increase both in the rate of glycogen synthesis (Figure 5D)
and in glycogen content (Figure 5E) in response to the adminis-
tration of both orexin-A and insulin than did the control (left)
muscle treated with the empty vector alone. The increase in
glycogen synthesis in the control muscle in b-less mice
in response to orexin-A plus insulin was almost similar to that
in WT mice after insulin injection alone (Figure 4C). These results
suggest that the stimulatory effect of orexin-A on insulin-induced
muscle glycogen synthesis requires b2-ARs in nonmyocyte cells
of skeletal muscle.
Conditioned Saccharin Drinking Activates the Orexin
System and Muscle Glucose Metabolism
Orexin neurons are associated with highly rewarded and moti-
vated behaviors, such as hedonic feeding, food seeking, and
addiction (Harris et al., 2005; Sakurai, 2007). The calorie-free
sweetener saccharin and glucose are often used as conditioned
reinforcers in animal experiments. Moreover, saccharin or
glucose ingestion increases the abundance of orexin mRNA in
the hypothalamus (Furudono et al., 2006). Oral carbohydrate
feeding also activates sympathetic outflow (Young and Lands-
berg, 1977; Welle et al., 1980). To examine whether orexin
neurons stimulate muscle glucose metabolism in response to
hedonic feeding motivated and conditioned with saccharin, we
trained mice to drink 1 ml of saccharin solution (10 mM) sponta-
neously within 10 min.
On the day of the experiment, similar exposure to saccharin
revealed that saccharin ingestion induced a significant increase
in the level of c-Fos immunoreactivity in orexin-positive neurons
in LH at 50 min after the onset of saccharin drinking (Figure 6A),
without affecting that in melanin-concentrating hormone (MCH)
neurons in LH (Figure 6B). We attempted to train orexin knockout
mice (Chemelli et al., 1999) to drink saccharin solution, but the
animals ingested only a small volume within 10 min (Figure 6C),
consistent with the previous observation that these mice are
not able to adapt to a restricted feeding schedule (Akiyama
et al., 2004; Mieda et al., 2004).Figure 2. Orexin-A-Induced 2DG Uptake in Skeletal Muscle of Mice Requires Muscle b2-AR Signaling
(A) Rate constant of 2DG uptake in peripheral tissues of WT or b-less mice (n = 6–8) at 2 hr after injection of orexin-A (5 pmol) or saline into VMH. *p < 0.05,
**p < 0.01 versus saline-injected animals or other control.
(B) Effects of orexin-A injected into VMHon phosphorylation of insulin signalingmolecules in the soleusmuscle ofWT or b-lessmice (n = 4–5) at 2 hr after injection.
Representative immunoblots with antibodies to the phosphorylated (p) or total (t) forms of the proteins are shown below the quantitative data.
(C) IRS-1-associated PI 3-kinase activity in the red gastrocnemius muscle at 2 hr after injection of orexin-A or saline into VMH of WT or b-less mice (n = 5).
(D) RT-PCR analysis of b1-, b2-, and b3-AR mRNAs in the soleus and EDL muscles of WT mice. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA
was examined as an internal control.
(E) Effects of prior i.p. administration of b-AR antagonists (1 mg/kg) on glucose uptake in the soleus of WT mice (n = 6–8) measured 2 hr after injection of orexin-A
or saline into VMH. yp < 0.05 versus orexin-A alone.
(F) RT-PCR analysis of b2-AR mRNA in skeletal muscle of left (L) and right (R) hind limbs of b-less mice after forced expression of mouse b2-AR in the right soleus
and red gastrocnemius under the control of the muscle-specific HSA gene promoter (8 days after electroporation). The left soleus and red gastrocnemius were
transfected with the empty vector alone. Data for untreated WT mice are shown for comparison. Eukaryotic translation elongation factor 2 (eEF2) mRNA was
examined as an internal control.
(G and H) 2DG uptake in skeletal muscle of the left and right hind limbs of b-less mice (n = 8) measured 8 days after electroporation as in (F) and at 2 hr after
administration of orexin-A (G) or saline (H) into VMH. All quantitative data are means ± SEM for the indicated numbers (n) of mice. Error bars are shown as SEM.etabolism 10, 466–480, December 2, 2009 ª2009 Elsevier Inc. 471
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Figure 3. Activation of VMH Neurons Mediates Orexin-A-Induced Muscle 2DG Uptake of Mice
(A) Concentration of orexin-A in hypothalamic nuclei at 2 hr after injection of the peptide (5 pmol) into VMH of mice (n = 5). *p < 0.05, **p < 0.01 versus correspond-
ing saline or other control.
(B) Immunohistofluorescence image of orexin neurons projecting to VMH of mice. Arrows indicate the close apposition of orexin-positive processes (green) and
SF1-positive neurons (red). Scale bar, 20 mm.
(C) Differential interference contrast image of a coronal slice of mouse brain including VMH (dark bilateral oval-shaped areas).
(D) Voltage recording from amouse VMH neuron exposed to orexin-A (500 nM) for the time indicated by the bar (left panel). The effects of addition and washout of
orexin-A on the firing rate of orexin-sensitive neurons (n = 16) is also shown (right panel). ACSF, artificial cerebrospinal fluid.
(E) Orexin-A–induced depolarization of a VMH neuron in the presence of tetrodotoxin (1 mM).
(F) NE turnover in the soleus and EDL of mice (n = 4–5) measured as in Figure 1G after injection of orexin-A with or without prior injection of the OX-R antagonist
SB334867 (250 pmol) into VMH.
(G) 2DG uptake in skeletal muscle of mice (n = 5–8) at 2 hr after injection of orexin-Awith or without prior injection of SB334867 into VMH. yp < 0.05 versus orexin-A
alone. All quantitative data are means ± SEM. Error bars are shown as SEM.We next examined the effects of saccharin drinking on insulin-
stimulated glucose metabolism in skeletal muscle. We injected
insulin (0.75 U/kg, i.v.) 40 min after the onset of saccharin472 Cell Metabolism 10, 466–480, December 2, 2009 ª2009 Elsevierdrinking and administered radioisotopes for measurement of
2DG uptake and glycogen synthesis 10 min after insulin injec-
tion (Figure 6D). Plasma glucose level was maintained constantInc.
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drinking significantly enhanced the stimulatory effects of insulin
on both 2DG uptake (Figure 6E) and glycogen synthesis
(Figure 6F) in the soleus, whereas it did not increase insulin-
induced 2DG uptake in WAT (Figure S7B). Saccharin drinking
alone (without insulin injection) showed a tendency to increase
2DG uptake and glycogen synthesis in the soleus muscle, but
this effect was not statistically significant (data not shown). There
were no differences in plasma insulin level between animals
drinking saccharin or water before as well as after insulin injec-
tion (Figure S7C), probably as a result of the anticipatory
response by training. In addition, plasma insulin concentration
did not change by treatment with SB334867 or ICI118551 in
animals drinking saccharin before and after insulin injection
(data not shown). Consistent with the results shown in Figures
2E, 3G, and 3H, injection of SB334867 into both sides of VMH
or i.p. injection of ICI 118551 abolished the effects of saccharin
on insulin-stimulated 2DG uptake and glycogen synthesis in
the soleus (Figures 6E and 6F) without affecting saccharin
drinking behavior (data not shown). SB334867 and ICI 118551
did not affect insulin-induced or basal 2DG uptake or glycogen
synthesis in the absence of saccharin drinking (data not shown).
Manifestation of the saccharin effects onmuscle glucosemetab-
olism required the training of mice with saccharin for several
days. Our results thus suggest that conditioned taste stimulation
with saccharin activates an orexin-MH-sympathetic nervous
system axis and thereby promotes insulin-induced muscle
glucose uptake and glycogen synthesis.
Conditioned Glucose Tasting Enhances Glucose
Metabolism through OX-Rs in the MH
Finally, mice were allowed to lick and taste a small volume of
glucose solution (2 g/kg) on each of three consecutive days,
were deprived of food overnight, and then were injected with
SB334867 or saline into both sides of VMH on the next day
10 min before the next scheduled exposure to glucose. The
blood glucose level after glucose ingestion was significantly
greater in mice injected with SB334867 than in those injected
with saline, whereas the plasma insulin levels did not differ
between the two groups (Figure 7A). These results suggest
that OX-Rs in the VMH and nearby area regulate blood glucose
level in response to oral glucose ingestion in a manner indepen-
dent of plasma insulin. Manifestation of the SB334867 effect on
muscle glucose metabolism required the training of mice with
glucose for several days. In contrast, SB334867 injected into
VMH had no effect on the plasma glucose, as well as insulin
concentration, when glucose was administered i.p., even after
training of the mice with glucose tasting (Figure 7B). Further-
more, oral glucose ingestion showed higher glucose level in
orexin knockout mice than in WT mice, although plasma insulin
level was significantly higher in orexin knockout mice
(Figure 7C).
DISCUSSION
Our present findings reveal that orexin-A and its receptors in the
MH regulate glucose uptake and glycogen synthesis in skeletal
muscle via stimulation of sympathetic nerves and the activation
of b2-ARs in both myocytes and nonmyocyte cells, triggeringCell Mboth direct activation of the insulin signaling pathway in myo-
cytes and an increase in the availability of insulin to these cells.
We also found that hedonic feeding conditioned with sweet
taste stimulation activates the orexin-MH-sympathetic nervous
system axis and thereby stimulates muscle glucosemetabolism.
Role of Sympathetic Nerves in the Orexin-A-Regulated
Muscle Glucose Metabolism
Studies with catecholamine administration have suggested
that the sympathetic nervous system inhibits the insulin
signaling pathway in peripheral tissues. However, our present
data show that the preferential stimulation of sympathetic
nerves and subsequent b2-AR signaling result in activation of
the insulin signaling pathway in skeletal muscle in vivo. Our
results thus suggest that the effects of sympathetic nerves
on muscle glucose metabolism may differ in some instances
from those of catecholamine administration. Consistent with
this notion, a b2-AR-specific agonist was previously shown to
increase glucose uptake in L6 myocytes via activation of PI
3-kinase, with this effect being inhibited by protein kinase A
(PKA) (Nevzorova et al., 2006). Indeed, orexin-A injection into
VMH did not increase a2AMPK activity in skeletal muscle,
which is regulated via an a-adrenergic mechanism. Further-
more, the activity of muscle glycogen phosphorylase a, which
is increased by PKA or a high cytosolic free Ca2+ concentra-
tion, was not significantly affected in response to orexin-A
injection. Although humoral factors might be required for the
orexin’s effect, these results suggest that orexin-A injected
into VMH enhances glucose uptake and glycogen synthesis
through a specific b2-AR signaling pathway but not PKA or
AMPK. Recently, b-less mice have been shown to have better
insulin sensitivity in insulin tolerance test than did WT mice
(Asensio et al., 2005). This phenomenon may be due to the
increased level of plasma epinephrine secreted from adrenal
medulla in response to hypoglycemia, which inhibits muscle
insulin signaling via activation of PKA-signaling pathway in
WT mice.
Our data also indicate that b2-ARs in nonmyocyte cells of
skeletal muscle are required for the enhancement by orexin-
A of insulin-induced glycogen synthesis. Insulin delivery to
skeletal muscle cells via blood vessels plays a key role in
whole-body glucose disposal (Clerk et al., 2006; Chiu et al.,
2008). Both b2-ARs in blood vessels (Guimara˜es and Moura,
2001) and insulin (Sowers, 2004) stimulate vascular relaxation.
Our observation that orexin-A enhanced the insulin-induced
tyrosine phosphorylation of the IR in skeletal muscle suggests
that orexin-A injected into VMH might promote insulin delivery
to muscle cells by activating b2-ARs. Our findings thus
suggest that an orexin-A-sympathetic nerve-b2-AR signaling
system regulates glucose metabolism in muscle as follows:
first, in the presence of a low plasma concentration of insulin,
orexin-A in the MH triggers activation of PI 3-kinase, Akt, and
other downstream components of the insulin signaling
pathway in skeletal muscle, at least in part through activation
of b2-ARs in myocytes; and second, in the presence of high
plasma insulin levels, orexin-A enhances insulin delivery to
myocytes through activation of b2-ARs in blood vessels and
thereby potentiates the effects of insulin on muscle glucose
metabolism.etabolism 10, 466–480, December 2, 2009 ª2009 Elsevier Inc. 473
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Figure 4. Orexin-A Enhances Insulin-Induced 2DG Uptake and Glycogen Synthesis in Skeletal Muscle of Mice
(A) Experimental protocol for measurement of glucose metabolism in skeletal muscle of mice treated with orexin-A and insulin.
(B and C) Rate constant of 2DG uptake (n = 5) and rate of glycogen synthesis (n = 7–9), respectively, in the soleus measured 2 hr after orexin-A injection into VMH
and subsequent i.v. injection of insulin. *p < 0.05, **p < 0.01 versus corresponding saline value.
(D and E) Phosphorylation of the b subunit of the IR (Tyr1146), Akt (Ser473), and GSK3b (Ser9) in the soleus (n = 3) at 2 hr after orexin-A injection into VMH and
subsequent i.v. injection of insulin. Immunoblots are shown in (D) and quantitative data in (E).474 Cell Metabolism 10, 466–480, December 2, 2009 ª2009 Elsevier Inc.
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Orexin Regulation of Muscle Glucose MetabolismVMH as a Key Target for Orexin-A in Its Effects on
Skeletal Muscle
Our present data implicate VMH as a key target for orexin-A in its
activation of glucose metabolism in skeletal muscle. VMH was
found to contain many cells activated by orexin-A. The effects
of orexin-A on the sympathetic nervous system and glucose
metabolism differ from those of electrical stimulation or injection
of leptin in part. Electrical stimulation of VMH elicits sympathetic
nerve activity in most peripheral tissues, including the adrenal
medulla (Saito et al., 1989a), and injection of leptin into VMH
increases plasma catecholamine levels (Satoh et al., 1999),
whereas injection of orexin-A into VMHdid not increase epineph-
(F) Activity of glycogen synthase a in the soleus (n = 7) at 2 hr after injection of orexin-A into VMH and subsequent i.v. injection of insulin. Data are presented as the
ratio of activity measured in the absence to that measured in the presence of glucose 6-phosphate (G6P). All quantitative data are means ± SEM. Error bars are
shown as SEM.
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Figure 5. Enhancement of Insulin-Induced
Glycogen Synthesis by Orexin-A Requires
b2-ARs in Nonmyocyte Cells of Skeletal
Muscle
(A) Effects of orexin-A and insulin administered as
in Figure 4A on the rate of glycogen synthesis in
the left and right soleus muscles of b-less mice
(n = 5) expressing the b2-AR in the right soleus
under the control of the HSA gene promoter as in
Figure 2F. *p < 0.05, **p < 0.01 versus correspond-
ing control value.
(B) RT-PCR analysis of b2-ARmRNA in the left and
right soleus of b-less mice (n = 6) expressing the
b2-AR under the control of the CAG promoter in
the right soleus. Mice were examined at 5 days
after electroporation.
(C) Hematoxylin-eosin (HE) staining (upper panels)
and EGFP fluorescence analysis (lower panels) of
skeletal muscle after electroporation with a vector
encoding EGFP under the control of the CAG (left
panels) or HSA gene (right panels) promoters.
Arrows indicate blood vessels in the soleus
muscle expressing EGFP or not; the inset shows
at higher magnification the EGFP-positive blood
vessel in the boxed region. Dotted lines demarcate
the soleus and gastrocnemius muscles, with the
asterisks indicating the gastrocnemius.
(D and E) Rate of glycogen synthesis and glycogen
content, respectively, in the soleus of b-less mice
(n = 10) expressing the b2-AR under the control
of the CAG promoter in the right soleus. All quan-
titative data are means ± SEM. Error bars are
shown as SEM.
rine secretion from the adrenal medulla or
affect sympathetic nerve activity in WAT.
Our preliminary data also reveal that
injection of orexin-A into theMH activates
glucose metabolism and norepinephrine
turnover in the heart, as well as in skeletal
muscle, but not in BAT (authors’ unpub-
lished data). Thus, in contrast to the
effects of leptin, orexin-A in VMH and
nearby area selectively regulates some
peripheral tissues, including skeletal muscle, through the stimu-
lation of sympathetic nerves.
Physiological Role of the Orexin System in Muscle
Glucose Metabolism
Taste stimulation has been associated with meal-induced ther-
mogenesis (LeBlanc and Brondel, 1985; Diamond et al., 1985;
LeBlanc, 2000), and oral sucrose feeding activates the sympa-
thetic nervous system (Young and Landsberg, 1977; Welle
et al., 1980). The initial phase of a meal is thought to be the
origin of an increase in heat production not necessarily associ-
ated with the absorption or digestion of nutrients and coincidesCell Metabolism 10, 466–480, December 2, 2009 ª2009 Elsevier Inc. 475
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tions (Diamond et al., 1985; LeBlanc and Brondel, 1985). In
humans, a highly palatable meal results in greater thermogene-
sis than does a nonpalatable meal consisting of the homoge-
nized same palatable meal (LeBlanc and Brondel, 1985).
After a carbohydrate-rich meal, forearm glucose uptake was
reduced pronouncedly by b-adrenergic blockade in human
(Astrup et al., 1990). In contrast, forced feeding of rats and
humans by gavage resulted in a reduction in thermogenesis
and subsequent obesity (Rothwell and Stock, 1978; LeBlanc
et al., 1984; Saito et al., 1989b). Consistent with this notion,
orexin-A injection into VMH showed greater effect on glucose
uptake in red type of skeletal muscles than in white type of
muscles. Red type of muscles has many mitochondria, a key
organelle for thermogenesis.
We used saccharin and glucose as the conditioned reinforcers
to activate orexin neurons in mice. The situation may be more
complicated in humans as well as rodents, however, with other
factors such as the palatability of foods, the environment during
a meal, and habituation to the feeding regimen possibly contrib-
uting to activation of this system.
In the present study, we examined the effect of bolus
injection of insulin and orexin-A on glucose metabolism and
insulin signaling, maintaining blood glucose level. Our prelimi-
nary study showed that bolus injection of insulin was more
effective than constant infusion of insulin (hyperinsulinemic-
euglycemic camp) to manifest the synergic effect of hypotha-
lamic orexin-A and insulin (data not shown). Furthermore, the
action of orexin-A on glucose uptake is shorter than that of
leptin. The activation of orexin neurons may also be terminated
by high glucose concentration soon after the meal is consumed
(Yamanaka et al., 2003). The orexin system is thus transiently
activated by conditioned taste stimulation and enhances
glucose utilization in skeletal muscle induced by a rapid
increase in the circulating insulin level, rather than continuous
hyperinsulinemia.
It is also possible that the orexin-MH–sympathetic nervous
system axis regulates muscle glucose metabolism during fast-
ing. Orexin neurons are activated by fasting (Diano et al., 2003)
and are associated with food-seeking behavior (Sakurai et al.,
1998) and adaptive augmentation of arousal level during fasting
(Yamanaka et al., 2003). Although the activity of sympathetic
nerves in certain tissues such as BAT decreases markedly in
response to fasting, that in skeletal muscle does not (DullooCell Met al., 1988). The orexin-MH system might thus support the
metabolic demand required for fasting-related behaviors, such
as food seeking or fight-or-flight, by maintaining glucose utiliza-
tion in skeletal muscle.
Collectively, our present results suggest that the orexin-
MH–sympathetic nervous system axis plays an important
role in the regulation of glucose metabolism in skeletal muscle.
The b2-adrenergic receptor in both myocytes and nonmyocyte
cells of skeletal muscle is involved in the regulation. Glucose
metabolism in skeletal muscle is thus regulated by the nonho-
meostatic regulatory system associated with taste stimulation,
motivation, and anticipation. It is also possible that glucose
metabolism in skeletalmuscle is associatedwith sleepandwake-
fulness through the orexin-MH–sympathetic nervous system
axis.
EXPERIMENTAL PROCEDURES
Animals
Male Sprague-Dawley rats (Nihon SLC, Hamamatsu, Japan), C57BL/6J mice
(Nihon SLC), b-less mice (Bachman et al., 2002), and orexin knockout mice
(Chemelli et al., 1999) were studied at 10 to 13weeks of age, with the exception
that electrophysiological studies were performed with 4-week-old mice.
Animals were housed individually in plastic cages at 24 ± 1C with lights on
from 06:00 to 18:00 hr and were maintained with free access to a laboratory
diet (MF; Oriental Yeast, Tokyo, Japan) and water.
All animal studies were reviewed and approved by the appropriate ethics
committee in National Institute for Physiological Sciences and were performed
according to institutional guidelines concerning the care and handling of
experimental animals.
Statistical Analysis
Data are presented as mean ± SEM. Data were evaluated by the unpaired or
paired Student’s t test or by analysis of variance followed by Bonferroni’s
multiple-range test. A P value of < 0.05 was considered statistically significant.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, two
tables, and eight figures and can be found with this article online at http://
www.cell.com/cell-metabolism/supplemental/S1550-4131(09)00309-X.
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the Center for Analytical Instruments at the National Institute for Basic BiologyFigure 6. Conditioned Saccharin Drinking Activates the Hypothalamic Orexin System and Thereby Stimulates Muscle Glucose Metabolism
(A) Immunohistofluorescence analysis of c-Fos expression (red) in neurons positive for orexin-like immunoreactivity (green) in the LH of mice at 50 min after the
onset of conditioned drinking of saccharin solution or water. The boxed regions of the upper panels are shown at higher magnification in the lower panels. Arrow-
heads indicate c-Fos-positive orexin neurons. Scale bars, 20 mm. The percentage of c-Fos-positive cells among 120 orexin neurons in the LH and perifornical area
in each of three mice is also shown. **p < 0.01 versus corresponding control values.
(B) Immunohistofluorescence analysis of c-Fos expression (red) in neurons positive for MCH-like immunoreactivity (green) within the LH of mice at 50 min after
conditioned drinking of saccharin solution or water. Scale bars, 20 mm.
(C) Volume of saccharin solution drank during 10 min by prepro-orexin knockout (Orexin-KO) or WT mice (n = 5) subjected to the training protocol for saccharin
drinking.
(D) Experimental protocol for analysis of muscle glucose metabolism after conditioned saccharin drinking. Mice were trained to drink saccharin solution during
10 min beginning at 10:00 hr for 3 days before experiments.
(E and F) Rate constant of 2DG uptake and rate of glycogen synthesis, respectively, in the soleus muscle of mice (n = 7–9) after conditioned saccharin drinking
with or without prior injection of SB334867 (into VMH) or ICI 118551 (i.p.) or of subsequent injection of insulin (i.v.). All quantitative data are means ± SEM. Error
bars are shown as SEM. **p < 0.05 versus corresponding control values.etabolism 10, 466–480, December 2, 2009 ª2009 Elsevier Inc. 477
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Figure 7. Conditioned Tasting of Glucose Solution Enhances Whole-Body Glucose Metabolism through OX-Rs in VMH
(A) Time course of blood glucose concentration after conditioned oral glucose ingestion (2 g/kg) in mice (n = 7) deprived of food overnight and injected with
SB334867 or saline into VMH (left panel). The area under the curves of blood glucose concentration versus time (middle panel): *p < 0.05, **p < 0.01 versus
corresponding saline value. Time course of plasma insulin level (right panel): *p < 0.05 versus corresponding value for time 0.
(B) Time course of blood glucose concentration after i.p. glucose injection (2 g/kg) in mice (n = 5) deprived of food overnight and injected with SB334867 or saline
into VMH (left panel). The area under the curves of blood glucose concentration versus time (middle panel) and plasma insulin level (right panel) are also shown.
(C) Time course of blood glucose concentration after conditioned oral glucose ingestion (2 g/kg) in Orexin-KO mice (n = 10–11) deprived of food overnight (left
panel). The area under the curves of blood glucose concentration versus time (middle panel): *p < 0.05, versus corresponding saline value. Plasma insulin level
(right panel): *p < 0.05 versus corresponding value for time 0. Data are means ± SEM. Error bars are shown as SEM.(NIBB, Okazaki, Japan) for DNA sequencing, and the Center for Radioisotope
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